- COMMENT
Improving data sharing to increase the efficiency of antibiotic R&D
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery 20, 1-2 (2021)
doi: https://doi.org/10.1038/d41573-020-00185-y
References
Erwin, A. L. Antibacterial drug discovery targeting the lipopolysaccharide biosynthetic enzyme. Cold Spring Harb. Perspect. Med. https://doi.org/10.1101/cshperspect.a025304 (2016)
Kalinin, D. V. & Holl, R. LpxC inhibitors: a patent review (2010-2016). Expert Opin. Ther. Pat. 27, 1227–1250 (2017).
Butler, M. S. & Paterson, D. L. Antibiotics in the clinical pipeline in October 2019. J. Antibiot. 73, 329–364 (2020).
Cohen, F. et al. Optimization of LpxC inhibitors for antibacterial activity and cardiovascular safety. ChemMedChem 14, 1–14 (2019).
Krause, K. M. et al. Potent LpxC inhibitors with in vitro activity against multidrug-resistant pseudomonas aeruginosa. Antimicrob. Agents Chemother. 63, e00977-19 (2019)
Competing Interests
Z.Z. is a co-founder, shareholder and the CEO of Forge Therapeutics. Forge Therapeutics currently receives funding support from CARB-X. K.O. is the PI for grants for CARB-X from the Biomedical Advanced Research & Development Authority (Cooperative Agreement No. 6 IDSEP160030), the Wellcome Trust, the UK Department of Health & Social Care (GAMRIF), the German Federal Ministry of Education & Research (BMBF) and the Bill & Melinda Gates Foundation. The views expressed herein are personal, and are not necessarily the views of CARB-X or any CARB-X funder. The other authors declare no competing interests.